

ALS Biomarkers of Neurodegeneration, Astrogliosis, and Inflammation

Original Placebo Randomization vs. CNM-Au8 30 mg Treatment

Results from the HEALEY ALS Platform Trial Long-Term Open Label Extension




Marjan Sepassi, PharmD; James D. Berry, MD, MPH; Nicholas Maragakis, MD; Sabrina Paganoni, MD, PhD; Melanie Quintana, PhD; Eric A. Macklin, PhD; Benjamin R. Saville, PhD; Jinsy Andrews, MD; Jeremy Shefner, MD, PhD; Michelle A. Detry, PhD; Elijah Stommel MD; Meghan Hall; Mariah Connolly; Gale Kittle; Marianne Chase; Alex Sherman; Hong Yu; Lindsay Pothier; Kristin Drake, MBA; Lori Chibnik, PhD, MPH; Marie-Abele Bind, PhD; Matteo Vestrucci, PhD; Austin Rynders, RN; Jacob Evan; Jeremy Evan, PA-C; Karen S. Ho, PhD, MSc; Alan Hartford, PhD; Ben Greenberg, MD; Merit E. Cudkowicz, MD; and Michael T. Hotchkiss for the HEALEY ALS Platform Trial Study Group

RESULTS: Long-Term Treatment with CNM-Au8 Resulted in Significant Differences in Decline of NfL, GFAP, and CHI3L1 (YKL-40) Levels versus Original Randomization to Placebo

Neurofilament Light (NfL) (All Evaluable, Pre-planned Analysis)


Plasma NfL Geometric Mean Change (CNM-Au8 30mg)
Within Regimen Analysis | Quantexix 4NPA
All Evaluable with Baseline and Post-Baseline Data (n=99)
LS Geometric Mean Difference ± SEM



MMRM included all evaluable clinical visits. All visits with ≥ 10 participants (for either group) are graphed.
LS Geometric mean difference: *** p<0.001, ** p<0.01, * p<0.05, ^ p<0.10

Neurofilament Light (NfL) (Limb Onset, Post Hoc)


Plasma NfL Geometric Mean Change (CNM-Au8 30mg)
Limb Onset Subset
Within Regimen Analysis | Quantexix 4NPA
All Evaluable with Baseline, n=83; LS Geometric Mean Difference ± SEM



MMRM included all evaluable clinical visits. All visits with ≥ 10 participants (for either group) are graphed.
LS Geometric mean difference: *** p<0.001, ** p<0.01, * p<0.05, ^ p<0.10

Glial Fibrillary Acidic Protein (GFAP) (All Evaluable, Post Hoc)


Plasma GFAP Geometric Mean Change (CNM-Au8 30 mg)
Within Regimen Analysis | Quantexix 4NPA
All Evaluable with Baseline and Post-Baseline Data (n=99)
LS Geometric Mean Difference ± SEM



MMRM included all evaluable clinical visits. All visits with ≥ 10 participants (for either group) are graphed.
LS Geometric mean difference: *** p ≤ 0.001, ** p ≤ 0.01, * p < 0.05, ^ p ≤ 0.10

Glial Fibrillary Acidic Protein (GFAP) (Limb Onset, Post Hoc)


Plasma GFAP Geometric Mean Change (CNM-Au8 30 mg)
Limb Onset Subset
Within Regimen Analysis | Quantexix 4NPA
All Evaluable with Baseline and Post-Baseline Data (n=82)
LS Geometric Mean Difference ± SEM



MMRM included all evaluable clinical visits. All visits with ≥ 10 participants (for either group) are graphed.
LS Geometric mean difference: *** p ≤ 0.001, ** p ≤ 0.01, * p < 0.05, ^ p ≤ 0.10

Chitinase-3-Like Protein 1 (YKL-40) (All Evaluable, Post Hoc)


Plasma CHI3L1 (YKL-40) Geometric Mean Change (CNM-Au8 30mg)
Within Regimen Analysis | nVector
All Evaluable with Baseline and Post-Baseline Data (n=94)
LS Geometric Mean Difference ± SEM



MMRM included all evaluable clinical visits. All visits with ≥ 10 participants (for either group) are graphed.
LS Geometric mean difference: *** p<0.001, ** p<0.01, * p < 0.05, ^ p<0.10

Chitinase-3-Like Protein 1 (YKL-40) (Limb Onset, Post Hoc)

Plasma CHI3L1 (YKL-40) Geometric Mean Change (CNM-Au8 30 mg)
Limb Onset Subset
Within Regimen Analysis | nVector
All Evaluable with Baseline and Post-Baseline Data (n=80)
LS Geometric Mean Difference ± SEM



MMRM included all evaluable clinical visits. All visits with ≥ 10 participants (for either group) are graphed.
LS Geometric mean difference: *** p<0.001, ** p<0.01, * p < 0.05, ^ p<0.10

Methods

Mixed Model Repeat Measure (MMRM) included baseline covariates: time from symptom onset, pre-treatment ALSFRS-R slope, background edaravone and riluzole treatment, and covariate interaction by week. Analyses includes all participants with evaluable baseline and post-baseline values.

Acknowledgements: We are indebted to the participants and investigators of the HEALEY ALS Platform Trial.

